Simvastatin Drug Interactions
157Total Interactions
49Severe
57Moderate
1Mild
| Drug | Severity | Summary |
|---|---|---|
| Acipimox | SEVERE | Acipimox is predicted to increase the risk of rhabdomyolysis when given with Simvastatin. Manufac... |
| Alcohol | SEVERE | Alcohol -induced liver disease increases the risk of hepatotoxicity in those taking Simvastatin. ... |
| Amiodarone | SEVERE | Amiodarone increases the exposure to Simvastatin. Manufacturer advises adjust Simvastatin dose. |
| Aprepitant | SEVERE | Aprepitant is predicted to increase the exposure to Simvastatin. Manufacturer advises monitor and... |
| Atazanavir | SEVERE | Atazanavir is predicted to increase the exposure to Simvastatin. Manufacturer advises avoid. |
| Bemiparin | SEVERE | Simvastatin might increase the risk of hepatotoxicity when given with Bemiparin (high-dose). Manu... |
| Bezafibrate | SEVERE | Bezafibrate increases the risk of rhabdomyolysis when given with Simvastatin. Manufacturer advise... |
| Ceritinib | SEVERE | Ceritinib is predicted to increase the exposure to Simvastatin. Manufacturer advises avoid. |
| Ciclosporin | SEVERE | Ciclosporin markedly to very markedly increases the exposure to Simvastatin. Manufacturer advises... |
| Ciprofibrate | SEVERE | Ciprofibrate increases the risk of rhabdomyolysis when given with Simvastatin. Manufacturer advis... |
| Clarithromycin | SEVERE | Clarithromycin is predicted to increase the exposure to Simvastatin. Manufacturer advises avoid. |
| Cobicistat | SEVERE | Cobicistat is predicted to increase the exposure to Simvastatin. Manufacturer advises avoid. |
| Colchicine | SEVERE | Colchicine has been reported to cause rhabdomyolysis when given with Simvastatin. Manufacturer ad... |
| Crizotinib | SEVERE | Crizotinib is predicted to increase the exposure to Simvastatin. Manufacturer advises monitor and... |
| Dalteparin | SEVERE | Simvastatin might increase the risk of hepatotoxicity when given with Dalteparin (high-dose). Man... |
| Daptomycin | SEVERE | Simvastatin is predicted to increase the risk of rhabdomyolysis when given with Daptomycin. Manuf... |
| Darunavir | SEVERE | Darunavir is predicted to increase the exposure to Simvastatin. Manufacturer advises avoid. |
| Diltiazem | SEVERE | Diltiazem moderately increases the exposure to Simvastatin. Manufacturer advises monitor and adju... |
| Dronedarone | SEVERE | Dronedarone moderately increases the exposure to Simvastatin. Manufacturer advises monitor and ad... |
| Elafibranor | SEVERE | Elafibranor might increase the risk of muscle effects when given with Simvastatin. Manufacturer a... |
| Enoxaparin | SEVERE | Simvastatin might increase the risk of hepatotoxicity when given with Enoxaparin (high-dose). Man... |
| Erythromycin | SEVERE | Erythromycin markedly increases the exposure to Simvastatin. Manufacturer advises avoid. |
| Fenofibrate | SEVERE | Fenofibrate increases the risk of rhabdomyolysis when given with Simvastatin. Manufacturer advise... |
| Fluconazole | SEVERE | Fluconazole is predicted to increase the exposure to Simvastatin. Manufacturer advises monitor an... |
| Fosamprenavir | SEVERE | Fosamprenavir is predicted to increase the exposure to Simvastatin. Manufacturer advises avoid. |
| Fostemsavir | SEVERE | Fostemsavir is predicted to increase the exposure to Simvastatin. Manufacturer advises adjust sta... |
| Fusidate | SEVERE | Fusidate has been reported to cause rhabdomyolysis when given with Simvastatin. Manufacturer advi... |
| Gemfibrozil | SEVERE | Gemfibrozil modestly increases the exposure to Simvastatin. Manufacturer advises avoid. |
| Grapefruit | SEVERE | Grapefruit juice increases the exposure to Simvastatin. Manufacturer advises avoid. |
| Idelalisib | SEVERE | Idelalisib is predicted to increase the exposure to Simvastatin. Manufacturer advises avoid. |
| Imatinib | SEVERE | Imatinib moderately increases the exposure to Simvastatin. Manufacturer advises monitor and adjus... |
| Isavuconazole | SEVERE | Isavuconazole is predicted to increase the exposure to Simvastatin. Manufacturer advises monitor ... |
| Itraconazole | SEVERE | Itraconazole is predicted to increase the exposure to Simvastatin. Manufacturer advises avoid. |
| Ketoconazole | SEVERE | Ketoconazole is predicted to increase the exposure to Simvastatin. Manufacturer advises avoid. |
| Letermovir | SEVERE | Letermovir is predicted to increase the exposure to Simvastatin. Manufacturer advises avoid. |
| Lopinavir | SEVERE | Lopinavir is predicted to increase the exposure to Simvastatin. Manufacturer advises avoid. |
| Miconazole | SEVERE | Miconazole (including the oral gel) is predicted to increase the exposure to Simvastatin. Manufac... |
| Mifepristone | SEVERE | Mifepristone very markedly increases the exposure to Simvastatin. Manufacturer advises caution. |
| Netupitant | SEVERE | Netupitant is predicted to increase the exposure to Simvastatin. Manufacturer advises monitor and... |
| Nicotinic acid | SEVERE | Nicotinic acid might increase the risk of rhabdomyolysis when given with Simvastatin. Manufacture... |
| Nilotinib | SEVERE | Nilotinib is predicted to increase the exposure to Simvastatin. Manufacturer advises monitor and ... |
| Nirmatrelvir | SEVERE | Nirmatrelvir boosted with ritonavir is predicted to increase the concentration of Simvastatin. Ma... |
| Posaconazole | SEVERE | Posaconazole is predicted to increase the exposure to Simvastatin. Manufacturer advises avoid. |
| Ritonavir | SEVERE | Ritonavir is predicted to increase the exposure to Simvastatin. Manufacturer advises avoid. |
| Tinzaparin | SEVERE | Simvastatin might increase the risk of hepatotoxicity when given with Tinzaparin (high-dose). Man... |
| Tucatinib | SEVERE | Tucatinib is predicted to increase the exposure to Simvastatin. Manufacturer advises avoid. |
| Velpatasvir | SEVERE | Velpatasvir with sofosbuvir is predicted to increase the exposure to Simvastatin. Manufacturer ad... |
| Verapamil | SEVERE | Verapamil moderately increases the exposure to Simvastatin. Manufacturer advises monitor and adju... |
| Voriconazole | SEVERE | Voriconazole is predicted to increase the exposure to Simvastatin. Manufacturer advises avoid. |
| Amlodipine | MODERATE | Amlodipine causes a small increase in the exposure to Simvastatin. Manufacturer advises adjust Si... |
| Apalutamide | MODERATE | Apalutamide is predicted to decrease the exposure to Simvastatin. Manufacturer advises avoid or m... |
| Avacopan | MODERATE | Avacopan moderately increases the exposure to Simvastatin. Manufacturer advises adjust dose. |
| Belumosudil | MODERATE | Belumosudil is predicted to increase the exposure to Simvastatin. Manufacturer advises avoid or a... |
| Bempedoic acid | MODERATE | Bempedoic acid increases the exposure to Simvastatin. Manufacturer advises adjust Simvastatin dose. |
| Bosentan | MODERATE | Bosentan is predicted to decrease the exposure to Simvastatin. Manufacturer makes no recommendation. |
| Bulevirtide | MODERATE | Bulevirtide is predicted to increase the exposure to Simvastatin. Manufacturer advises avoid or m... |
| Cabazitaxel | MODERATE | Cabazitaxel is predicted to affect the exposure to Simvastatin. Manufacturer advises take 12 hour... |
| Carbamazepine | MODERATE | Carbamazepine moderately decreases the exposure to Simvastatin. Manufacturer advises monitor and ... |
| Ceftobiprole | MODERATE | Ceftobiprole is predicted to increase the concentration of Simvastatin. Manufacturer makes no rec... |
| Cenobamate | MODERATE | Cenobamate is predicted to decrease the exposure to Simvastatin. Manufacturer makes no recommenda... |
| Cilostazol | MODERATE | Cilostazol slightly increases the exposure to Simvastatin. Manufacturer advises caution. |
| Dabrafenib | MODERATE | Dabrafenib is predicted to decrease the exposure to Simvastatin. Manufacturer makes no recommenda... |
| Darolutamide | MODERATE | Darolutamide is predicted to increase the concentration of Simvastatin. Manufacturer advises moni... |
| Dasatinib | MODERATE | Dasatinib is predicted to increase the exposure to Simvastatin. Manufacturer makes no recommendat... |
| Efavirenz | MODERATE | Efavirenz is predicted to decrease the exposure to Simvastatin. Manufacturer makes no recommendat... |
| Elbasvir | MODERATE | Elbasvir with grazoprevir is predicted to increase the exposure to Simvastatin. Manufacturer advi... |
| Elexacaftor | MODERATE | Elexacaftor is predicted to increase the exposure to Simvastatin. Manufacturer advises caution. |
| Eltrombopag | MODERATE | Eltrombopag is predicted to increase the exposure to Simvastatin. Manufacturer advises monitor an... |
| Enzalutamide | MODERATE | Enzalutamide is predicted to decrease the exposure to Simvastatin. Manufacturer advises caution. |
| Eslicarbazepine | MODERATE | Eslicarbazepine moderately decreases the exposure to Simvastatin. Manufacturer advises monitor an... |
| Etravirine | MODERATE | Etravirine is predicted to decrease the exposure to Simvastatin. Manufacturer makes no recommenda... |
| Fosphenytoin | MODERATE | Fosphenytoin is predicted to decrease the exposure to Simvastatin. Manufacturer makes no recommen... |
| Fostamatinib | MODERATE | Fostamatinib slightly increases the exposure to Simvastatin. Manufacturer advises monitor adverse... |
| Givinostat | MODERATE | Givinostat might increase the exposure to Simvastatin. Manufacturer advises monitor. |
| Glecaprevir | MODERATE | Glecaprevir with pibrentasvir moderately increases the exposure to Simvastatin. Manufacturer advi... |
| Grazoprevir | MODERATE | Grazoprevir with elbasvir is predicted to increase the exposure to Simvastatin. Manufacturer advi... |
| Ivosidenib | MODERATE | Ivosidenib might affect the exposure to Simvastatin. Manufacturer advises avoid or monitor. |
| Ledipasvir | MODERATE | Ledipasvir with sofosbuvir is predicted to increase the exposure to Simvastatin. Manufacturer adv... |
| Leflunomide | MODERATE | Leflunomide is predicted to increase the exposure to Simvastatin. Manufacturer advises caution. |
| Lenacapavir | MODERATE | Lenacapavir is predicted to increase the concentration of Simvastatin. Manufacturer advises adjus... |
| Leniolisib | MODERATE | Leniolisib is predicted to increase the exposure to Simvastatin. Manufacturer advises avoid. |
| Lomitapide | MODERATE | Lomitapide increases the exposure to Simvastatin. Manufacturer advises monitor and adjust Simvast... |
| Lorlatinib | MODERATE | Lorlatinib is predicted to decrease the exposure to Simvastatin. Manufacturer makes no recommenda... |
| Mitotane | MODERATE | Mitotane is predicted to decrease the exposure to Simvastatin. Manufacturer advises caution. |
| Nevirapine | MODERATE | Nevirapine is predicted to decrease the exposure to Simvastatin. Manufacturer makes no recommenda... |
| Olaparib | MODERATE | Olaparib is predicted to increase the exposure to Simvastatin. Manufacturer advises caution. |
| Oxcarbazepine | MODERATE | Oxcarbazepine is predicted to decrease the exposure to Simvastatin. Manufacturer makes no recomme... |
| Pazopanib | MODERATE | Pazopanib might cause increased ALT concentrations when given with Simvastatin. Manufacturer advi... |
| Phenobarbital | MODERATE | Phenobarbital is predicted to decrease the exposure to Simvastatin. Manufacturer makes no recomme... |
| Phenytoin | MODERATE | Phenytoin is predicted to decrease the exposure to Simvastatin. Manufacturer makes no recommendat... |
| Pibrentasvir | MODERATE | Pibrentasvir with glecaprevir moderately increases the exposure to Simvastatin. Manufacturer advi... |
| Primidone | MODERATE | Primidone is predicted to decrease the exposure to Simvastatin. Manufacturer makes no recommendat... |
| Ranolazine | MODERATE | Ranolazine slightly increases the exposure to Simvastatin. Manufacturer advises adjust Simvastati... |
| Ribociclib | MODERATE | Ribociclib (high-dose) is predicted to increase the exposure to Simvastatin. Manufacturer advises... |
| Rifampicin | MODERATE | Rifampicin very markedly decreases the exposure to Simvastatin. Manufacturer makes no recommendat... |
| Roxadustat | MODERATE | Roxadustat is predicted to increase the exposure to Simvastatin. Manufacturer advises monitor adv... |
| Sarilumab | MODERATE | Sarilumab is predicted to decrease the exposure to Simvastatin. Manufacturer advises caution. |
| Sotorasib | MODERATE | Sotorasib is predicted to decrease the exposure to Simvastatin. Manufacturer makes no recommendat... |
| St John's wort | MODERATE | St John's wort is predicted to decrease the exposure to Simvastatin. Manufacturer makes no recomm... |
| Teriflunomide | MODERATE | Teriflunomide is predicted to increase the exposure to Simvastatin. Manufacturer advises caution. |
| Ticagrelor | MODERATE | Ticagrelor slightly to moderately increases the exposure to Simvastatin. Manufacturer advises adj... |
| Tocilizumab | MODERATE | Tocilizumab is predicted to decrease the exposure to Simvastatin. Manufacturer advises monitor an... |
| Vadadustat | MODERATE | Vadadustat increases the exposure to Simvastatin. Manufacturer advises monitor and adjust dose. |
| Venetoclax | MODERATE | Venetoclax is predicted to increase the exposure to Simvastatin. Manufacturer advises monitor. |
| Voclosporin | MODERATE | Voclosporin is predicted to increase the concentration of Simvastatin. Manufacturer advises monitor. |
| Voxilaprevir | MODERATE | Voxilaprevir with sofosbuvir and velpatasvir is predicted to increase the exposure to Simvastatin... |
| Encorafenib | MILD | Encorafenib is predicted to affect the exposure to Simvastatin. Manufacturer advises caution. |
| Acitretin | LOW | Both Simvastatin and Acitretin can increase the risk of hepatotoxicity. |
| Alectinib | LOW | Both Simvastatin and Alectinib can increase the risk of hepatotoxicity. |
| Anidulafungin | LOW | Both Simvastatin and Anidulafungin can increase the risk of hepatotoxicity. |
| Asparaginase | LOW | Both Simvastatin and Asparaginase can increase the risk of hepatotoxicity. |
| Bexarotene | LOW | Both Simvastatin and Bexarotene can increase the risk of hepatotoxicity. |
| Capecitabine | LOW | Both Simvastatin and Capecitabine can increase the risk of hepatotoxicity. |
| Carmustine | LOW | Both Simvastatin and Carmustine can increase the risk of hepatotoxicity. |
| Caspofungin | LOW | Both Simvastatin and Caspofungin can increase the risk of hepatotoxicity. |
| Clofarabine | LOW | Both Simvastatin and Clofarabine can increase the risk of hepatotoxicity. |
| Crisantaspase | LOW | Both Simvastatin and Crisantaspase can increase the risk of hepatotoxicity. |
| Cytarabine | LOW | Both Simvastatin and Cytarabine can increase the risk of hepatotoxicity. |
| Dactinomycin | LOW | Both Simvastatin and Dactinomycin can increase the risk of hepatotoxicity. |
| Decitabine | LOW | Both Simvastatin and Decitabine can increase the risk of hepatotoxicity. |
| Demeclocycline | LOW | Both Simvastatin and Demeclocycline can increase the risk of hepatotoxicity. |
| Doxycycline | LOW | Both Simvastatin and Doxycycline can increase the risk of hepatotoxicity. |
| Eravacycline | LOW | Both Simvastatin and Eravacycline can increase the risk of hepatotoxicity. |
| Fludarabine | LOW | Both Simvastatin and Fludarabine can increase the risk of hepatotoxicity. |
| Fluorouracil | LOW | Both Simvastatin and Fluorouracil can increase the risk of hepatotoxicity. |
| Flutamide | LOW | Both Simvastatin and Flutamide can increase the risk of hepatotoxicity. |
| Gemcitabine | LOW | Both Simvastatin and Gemcitabine can increase the risk of hepatotoxicity. |
| Heparin | LOW | Both Simvastatin and Heparin can increase the risk of hepatotoxicity. |
| Isoniazid | LOW | Both Simvastatin and Isoniazid can increase the risk of hepatotoxicity. |
| Isotretinoin | LOW | Both Simvastatin and Isotretinoin can increase the risk of hepatotoxicity. |
| Lenalidomide | LOW | Both Simvastatin and Lenalidomide can increase the risk of hepatotoxicity. |
| Lymecycline | LOW | Both Simvastatin and Lymecycline can increase the risk of hepatotoxicity. |
| Mercaptopurine | LOW | Both Simvastatin and Mercaptopurine can increase the risk of hepatotoxicity. |
| Methotrexate | LOW | Both Simvastatin and Methotrexate can increase the risk of hepatotoxicity. |
| Micafungin | LOW | Both Simvastatin and Micafungin can increase the risk of hepatotoxicity. |
| Minocycline | LOW | Both Simvastatin and Minocycline can increase the risk of hepatotoxicity. |
| Nelarabine | LOW | Both Simvastatin and Nelarabine can increase the risk of hepatotoxicity. |
| Neratinib | LOW | Both Simvastatin and Neratinib can increase the risk of hepatotoxicity. |
| Oxandrolone | LOW | Both Simvastatin and Oxandrolone can increase the risk of hepatotoxicity. |
| Oxymetholone | LOW | Both Simvastatin and Oxymetholone can increase the risk of hepatotoxicity. |
| Oxytetracycline | LOW | Both Simvastatin and Oxytetracycline can increase the risk of hepatotoxicity. |
| Paracetamol | LOW | Both Simvastatin and Paracetamol can increase the risk of hepatotoxicity. |
| Pegaspargase | LOW | Both Simvastatin and Pegaspargase can increase the risk of hepatotoxicity. |
| Pemetrexed | LOW | Both Simvastatin and Pemetrexed can increase the risk of hepatotoxicity. |
| Pomalidomide | LOW | Both Simvastatin and Pomalidomide can increase the risk of hepatotoxicity. |
| Pyrazinamide | LOW | Both Simvastatin and Pyrazinamide can increase the risk of hepatotoxicity. |
| Streptozocin | LOW | Both Simvastatin and Streptozocin can increase the risk of hepatotoxicity. |
| Testosterone | LOW | Both Simvastatin and Testosterone can increase the risk of hepatotoxicity. |
| Tetracycline | LOW | Both Simvastatin and Tetracycline can increase the risk of hepatotoxicity. |
| Thalidomide | LOW | Both Simvastatin and Thalidomide can increase the risk of hepatotoxicity. |
| Tigecycline | LOW | Both Simvastatin and Tigecycline can increase the risk of hepatotoxicity. |
| Tioguanine | LOW | Both Simvastatin and Tioguanine can increase the risk of hepatotoxicity. |
| Trabectedin | LOW | Both Simvastatin and Trabectedin can increase the risk of hepatotoxicity. |
| Valproate | LOW | Both Simvastatin and Valproate can increase the risk of hepatotoxicity. |
| Vitamin A | LOW | Both Simvastatin and Vitamin A can increase the risk of hepatotoxicity. |
| Vorasidenib | LOW | Both Simvastatin and Vorasidenib can increase the risk of hepatotoxicity. |
| Zidovudine | LOW | Both Simvastatin and Zidovudine can increase the risk of hepatotoxicity. |
Check Simvastatin against your patient's full medication list
InteractRx checks all drug combinations at once — built for GP surgery pharmacists.
Use the Free Checker